RESUMEN
The aim of our study was to determine whether, in patients with familiar combined hyperlipoproteinemia (FCH), ciprofibrate produces changes in paraoxonase, which acts as an antioxidant. A further aim was to estimate changes in serum levels of apolipoproteins, especially in apolipoprotein (apo) A-I and apoC-III. One of the mechanisms of action of fibrates is the activation apo A-I biosynthesis and the inhibition of apoC-III production. It is performed in the liver through peroxisome proliferator activated receptor (PPAR)-alpha activity. We found that ciprofibrate administration enhanced production of apoA-I and paraoxonase transport capacity. Decreases in paraoxonase during ciprofibrate treatment were not statistically significant but increases in serum levels of apoA-I were statistically significant. Levels of apoC-III were decreased, which suggests that ciprofibrate belongs in the group of fibrates that influences lipoprotein metabolism through PPAR-alpha activity.